Browsed by
Tag: apremilast

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study ?>

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

Oral OTEZLA(R) (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis. Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks; improvements…

Read More Read More

Apremilast for treating moderate to severe plaque psoriasis ?>

Apremilast for treating moderate to severe plaque psoriasis

Apremilast (Otezla) is not recommended for treating moderate to severe chronic plaque psoriasis in adults whose psoriasis has not improved with other treatments, or they have had side effects with these treatments in the past or there is a reason why they cannot have them. 1.1 Apremilast is not recommended within its marketing authorisation for treating psoriasis, that is, for treating adults with moderate to severe chronic plaque psoriasis that has not responded to systemic therapy, or systemic therapy is…

Read More Read More

Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks ?>

Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks

Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results. A significant portion of patients with psoriasis have scalp and nail involvement. Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. At week 16, apremilast produced greater improvements in Nail Psoriasis Severity Index score versus placebo; mean percent change:…

Read More Read More

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks ?>

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks; Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks; improvements were maintained through 32 weeks. Greater improvement was also seen in other efficacy and quality of life measures, including PASI-90, Physician’s Global Assessment (PGA), and Daily Life Quality Index (DLQI) for all doses. Global Health. Oral ponesimod in patients with chronic plaque psoriasis:…

Read More Read More

New Drug on the Block: Apremilast for Moderate-to-Severe Plaque Psoriasis ?>

New Drug on the Block: Apremilast for Moderate-to-Severe Plaque Psoriasis

Indicated for moderate-to-severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. New Drug on the Block: Apremilast for Moderate-to-Severe Plaque Psoriasis. Small-molecule drugs that block errant cell signalling pathways are also being developed and could form the basis of much-needed new topical treatments. For moderate and severe cases, topical treatment is impractical, and the benefits of systemic therapies are generally considered to outweigh the risks. Results from a phase III trial reported in July 2015 showed…

Read More Read More

Apremilast Chronic inflammatory disease Dermatology Phosphodiesterase inhibition Psoriasis Psoriatic arthritis Treatment ?>

Apremilast Chronic inflammatory disease Dermatology Phosphodiesterase inhibition Psoriasis Psoriatic arthritis Treatment

Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. 1NIHR Leeds Musculoskeletal Biomedical Research Unit, Section of Musculoskeletal Disease, Chapel Allerton Hospital, Chapel Town Road, Leeds, LS7 4SA UK; Centre for Skin Sciences, School of Life Sciences, University of Bradford, Bradford, UK; Department of Dermatology, Bradford NHS Trust, Bradford, UK. The latest generation of inhibitors selective for phosphodiesterase 4 (PDE4), such as apremilast and roflumilast, seems to have an improved therapeutic index. Keywords: Apremilast,…

Read More Read More

Drug on the Block: Apremilast for Moderate-to-Severe Plaque Psoriasis ?>

Drug on the Block: Apremilast for Moderate-to-Severe Plaque Psoriasis

Medscape – Psoriatic arthritis dosing for Otezla (apremilast), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Drugs & Diseases. Indicated for moderate-to-severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment of moderate to severe plaque psoriasis in a 12-week phase 2 study….

Read More Read More

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis ?>

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis. Haber SL(1), Hamilton S(2), Bank M(2), Leong SY(2), Pierce E(2). An overview of the use, safety, and efficacy of the PDE4 inhibitor apremilast, a promising new systemic therapy for treating psoriatic disease. Apremilast (Otezla – Celgene Europe Ltd.) is a novel orally administered immunomodulatory medicine licensed for the treatment of plaque psoriasis and psoriatic arthritis. Although apremilast is not approved to treat psoriasis, its use was associated with improvement…

Read More Read More

Healthcare Improvement Scotland comments on NICE Guidance – Apremilast for treating moderate to severe plaque psoriasis ?>

Healthcare Improvement Scotland comments on NICE Guidance – Apremilast for treating moderate to severe plaque psoriasis

NHSScotland should follow advice issued by the Scottish Medicines Consortium on new medicines. NICE STA Guidance 368 – Apremilast for treating moderate to severe plaque psoriasis. Apremilast for treating moderate to severe plaque psoriasis: A Single Technology Appraisal, March 2015. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Healthcare Improvement Scotland. Healthcare Improvement Scotland will submit comments on NICE Clinical Guidelines as a stakeholder on behalf of NHS Scotland. STA…

Read More Read More

Studies in psoriasis and psoriatic arthritis have demonstrated clinical activity of apremilast ?>

Studies in psoriasis and psoriatic arthritis have demonstrated clinical activity of apremilast

Studies in psoriasis and psoriatic arthritis have demonstrated clinical activity of apremilast. Efficacy in psoriasis is probably equivalent to methotrexate but less than that of monoclonal antibody inhibitors of tumour necrosis factor (TNFi). Studies in psoriasis and psoriatic arthritis have demonstrated clinical activity of apremilast. Efficacy in psoriasis is probably equivalent to methotrexate but less than that of monoclonal antibody inhibitors of tumour necrosis factor (TNFi). About Clinical Studies Learn About Clinical Studies. Laboratory data has demonstrated that apremilast decreases…

Read More Read More